RARITAN, NJ, Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with ...

The FDA has approved rivaroxaban (Xarelto, Johnson & Johnson) for stroke reduction in people with non-valvular atrial fibrillation. The label will include a boxed warning that people should not ...

Global pharma major Lupin Limited (Lupin) announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for ...

Trailing a big-selling rival from Pfizer and Bristol Myers Squibb, Bayer and Johnson & Johnson are looking for any opportunity to bolster their aging heart drug Xarelto. Now, just short of its 10th ...

Please provide your email address to receive an email when new articles are posted on . Xarelto was superior to aspirin for lowering the risk for recurrent stroke or systemic embolism among ...

Aurobindo has obtained the Food and Drug Administration’s green light for rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. Rivaroxaban tablets are used to reduce the risk of ...

The FDA approved the anticoagulant rivaroxaban (Xarelto, Janssen), to reduce the risk for stroke among patients with non-valvular atrial fibrillation (AF). Approval comes after data from the ROCKET-AF ...

Please provide your email address to receive an email when new articles are posted on . The prospective, multinational, investigator-initiated, single-arm, phase 4 HoT-PE trial included adults with ...